Literature DB >> 17924085

Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy.

Angela Kallwellis-Opara1, Alexander Staudt, Christiane Trimpert, Michel Noutsias, Uwe Kühl, Matthias Pauschinger, Heinz-Peter Schultheiss, Markus Grube, Michael Böhm, Gert Baumann, Uwe Völker, Heyo K Kroemer, Stephan B Felix.   

Abstract

Cardiac autoantibodies play a pathogenic role in dilated cardiomyopathy (DCM). Removal of antibodies by immunoadsorption (IA) induces hemodynamic improvement in DCM patients. The present study investigated the effects of IA on myocardial gene expression of the intermediate cytoskeletal filament desmin, which is upregulated in heart failure. RNA was isolated from five explanted non-failing hearts and five explanted failing hearts of DCM patients, and myocardial gene expression of desmin was estimated by real-time polymerase chain reaction (PCR). In a case-control study in six DCM patients (LVEF < 40%, NYHA II-III), IA and subsequent IgG substitution were performed at monthly intervals until month 3. Endomyocardial biopsies (EMBs) were obtained before and after IA (after 3-6 months). From six DCM patients without IA therapy (controls), EMBs were also obtained over a comparable time interval. Expression of the desmin gene was analyzed in these EMBs by real-time PCR. In failing explanted hearts, expression of desmin was significantly increased (0.88 +/- 0.12 vs 0.45 +/- 0.15 in non-failing hearts, P < 0.05). After IA, myocardial gene expression of desmin was significantly decreased (from 0.26 +/- 0.05 [baseline] to 0.14 +/- 0.04 [P < 0.05] vs baseline and controls). Removal of antibodies by IA modulates myocardial gene expression of desmin in DCM patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17924085     DOI: 10.1007/s00109-007-0263-5

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  35 in total

1.  The absence of desmin leads to cardiomyocyte hypertrophy and cardiac dilation with compromised systolic function.

Authors:  D J Milner; G E Taffet; X Wang; T Pham; T Tamura; C Hartley; A M Gerdes; Y Capetanaki
Journal:  J Mol Cell Cardiol       Date:  1999-11       Impact factor: 5.000

2.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

3.  Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution.

Authors:  A Staudt; F Schäper; V Stangl; A Plagemann; M Böhm; K Merkel; G Wallukat; K D Wernecke; K Stangl; G Baumann; S B Felix
Journal:  Circulation       Date:  2001-06-05       Impact factor: 29.690

Review 4.  Desmin: a major intermediate filament protein essential for the structural integrity and function of muscle.

Authors:  Denise Paulin; Zhenlin Li
Journal:  Exp Cell Res       Date:  2004-11-15       Impact factor: 3.905

5.  Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy.

Authors:  L X Fu; Y Magnusson; C H Bergh; J A Liljeqvist; F Waagstein; A Hjalmarson; J Hoebeke
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy.

Authors:  Alexander Staudt; Yvonne Staudt; Marcus Dörr; Marco Böhm; Fabian Knebel; Astrid Hummel; Lydia Wunderle; Malte Tiburcy; Klaus D Wernecke; Gert Baumann; Stephan B Felix
Journal:  J Am Coll Cardiol       Date:  2004-08-18       Impact factor: 24.094

7.  Missense mutations in desmin associated with familial cardiac and skeletal myopathy.

Authors:  L G Goldfarb; K Y Park; L Cervenáková; S Gorokhova; H S Lee; O Vasconcelos; J W Nagle; C Semino-Mora; K Sivakumar; M C Dalakas
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

8.  Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops.

Authors:  G Wallukat; A Wollenberger; R Morwinski; H F Pitschner
Journal:  J Mol Cell Cardiol       Date:  1995-01       Impact factor: 5.000

9.  Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy.

Authors:  J Schaper; R Froede; S Hein; A Buck; H Hashizume; B Speiser; A Friedl; N Bleese
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

10.  Disruption of muscle architecture and myocardial degeneration in mice lacking desmin.

Authors:  D J Milner; G Weitzer; D Tran; A Bradley; Y Capetanaki
Journal:  J Cell Biol       Date:  1996-09       Impact factor: 10.539

View more
  4 in total

Review 1.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

Review 2.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 3.  Drug-like actions of autoantibodies against receptors of the autonomous nervous system and their impact on human heart function.

Authors:  L R Herda; S B Felix; F Boege
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

4.  Immunoadsorption treatment for dilated cardiomyopathy: A PRISMA-compliant systematic review and meta-analysis.

Authors:  Ru-Tao Bian; Zhen-Tao Wang; Wei-Yu Li
Journal:  Medicine (Baltimore)       Date:  2021-07-02       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.